Agomelatine
Depressive Disorder
First Affiliated Hospital, Sun Yat-Sen UniversitySmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
90 Active assets in the Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Opc-34712 Dr. Albert Kar-Kin Chung | Phase 4 | A |
Saredutant Sanofi | Phase 3 | BBB |
S-Ketamine Chinese PLA General Hospital | Phase 4 | BBB |
VENLOR Janssen Research & Development, LLC | Phase 4 | BBB |
Paroxetine Brigham and Women's Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Agomelatine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →